[EN] BENZOXAZINONE DERIVATIVES AND ANALOGUES THEREOF AS MODULATORS OF TNF ACTIVITY [FR] DÉRIVÉS DE BENZOXAZINONE ET LEURS ANALOGUES EN TANT QUE MODULATEURS DE L'ACTIVITÉ DU TNF
Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazineacetic acid (zopolrestat) and congeners
作者:Banavara L. Mylari、Eric R. Larson、Thomas A. Beyer、William J. Zembrowski、Charles E. Aldinger、Michael F. Dee、Todd W. Siegel、David H. Singleton
DOI:10.1021/jm00105a018
日期:1991.1
unrecognized binding site on the aldosereductase (AR) enzyme with strong affinity for benzothiazoles was pursued for the design of novel, potentaldosereductaseinhibitors (ARIs). The first application of this hypothesis led to a novel series of 3,4-dihydro-4-oxo-3-(benzothiazolylmethyl)-1-phthalazineacetic+ + + acids. The parent of this series (207) was a potentinhibitor of AR from human placenta (IC50
[EN] BENZOXAZINONE DERIVATIVES AND ANALOGUES THEREOF AS MODULATORS OF TNF ACTIVITY<br/>[FR] DÉRIVÉS DE BENZOXAZINONE ET LEURS ANALOGUES EN TANT QUE MODULATEURS DE L'ACTIVITÉ DU TNF
申请人:UCB BIOPHARMA SPRL
公开号:WO2016198400A1
公开(公告)日:2016-12-15
A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogues thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neuradegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity
申请人:UCB Biopharma SPRL
公开号:US10287299B2
公开(公告)日:2019-05-14
A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neuradegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.